Greater tumor-infiltrating lymphocyte density is associated with improved overall survival outcomes in patients with ...
Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...
More information: Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2406070 Provided by University of Pittsburgh ...
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...
A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.
Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for select patients.
Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...
Find all the commercial and brand names of generic drug called Trastuzumab. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...